科倫藥業(002422.SZ)成功發行8億元的“20科倫(疫情防控債)SCP001”
格隆匯2月6日丨科倫藥業(002422.SZ)公佈,公司董事會於2020年2月6日獲悉,公司2020年第一期超短期融資券於2020年2月5日發行,募集資金已於2020年2月6日全額到賬。
該融資券簡稱“20科倫(疫情防控債)SCP001”,發行總額8億元,期限270天,票面利率2.90%,主體評級AA+。
該期超短期融資券募集資金主要用於償還有息債務及補充與抗擊新型冠狀病毒肺炎疫情相關的流動資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.